VC firm targets avian flu with $200M fund

Venture capital outfit Kleiner Perkins Caufield & Byers is starting a $200 million life sciences fund--the KPCB Pandemic and Bio Defense Fund--that will concentrate much of its money on the development of new therapies for avian flu. The venture group wants to use the money to speed preparations for a possible global pandemic. Venture capitalists will encourage biopharma and university groups to steer more research work toward bird flu. BioCryst Pharmaceuticals of Birmingham, which is developing the antiviral drug Peramivir, is first up for funding.

- read this report from Red Herring for more

PLUS: IBM and the Scripps Research Institute have announced a collaboration to conduct advanced research on pandemic viruses. Release

ALSO: A new think tank report says that an avian flu pandemic could kill 142 million people if the worst-case scenario comes to pass. Report

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.